Abstract:Background and objectives: Recent advances in Automated Insulin Delivery systems have been shown to dramatically improve glycaemic control and reduce the risk of hypoglycemia in people with type 1 diabetes. However, they are complex systems that require specific training and are not affordable for most. Attempts to reduce the gap with closed-loop therapies using advanced dosing advisors have so far failed, mainly because they require too much human intervention. With the advent of smart insulin pens, one of the main constraints (having reliable bolus and meal information) disappears and new strategies can be employed. This is our starting hypothesis, which we have validated in a very demanding simulator. In this paper, we propose an intermittent closed-loop control system specifically intended for multiple daily injection therapy to bring the benefits of artificial pancreas to the application of multiple daily injections. Methods: The proposed control algorithm is based on model predictive control and integrates two patient-driven control actions. Correction insulin boluses are automatically computed and recommended to the patient to minimize the duration of hyperglycemia. Rescue carbohydrates are also triggered to avoid hypoglycemia episodes. The algorithm can adapt to different patient lifestyles with customizable triggering conditions, closing the gap between practicality and performance. The proposed algorithm is compared with conventional open-loop therapy, and its superiority is demonstrated through extensive in silico evaluations using realistic cohorts and scenarios. The evaluations were conducted in a cohort of 47 virtual patients. We also provide detailed explanations of the implementation, imposed constraints, triggering conditions, cost functions, and penalties for the algorithm. Results: The in-silico outcomes combining the proposed closed-loop strategy with slow-acting insulin analog injections at 09:00 h resulted in percentages of time in range (TIR) (70-180 mg/dL) of 69.5%, 70.6%, and 70.4% for glargine-100, glargine-300, and degludec-100, respectively, and injections at 20:00 h resulted in percentages of TIR of 70.5%, 70.3%, and 71.6%, respectively. In all the cases, the percentages of TIR were considerably higher than those obtained from the open-loop strategy, being only 50.7%, 53.9%, and 52.2% for daytime injection and 55.5%, 54.1%, and 56.9% for nighttime injection. Overall, the occurrence of hypoglycemia and hyperglycemia was notably reduced using our approach. Conclusions: Event-triggering model predictive control in the proposed algorithm is feasible and may meet clinical targets for people with type 1 diabetes.

Using an Online Disturbance Rejection and Anticipation System to Reduce Hyperglycemia in a Fully Closed-Loop Artificial Pancreas System

Prior-knowledge-embedded Model Predictive Control for Blood Glucose Regulation: Towards Efficient and Safe Artificial Pancreas

An Adaptive Disturbance Rejection Controller for Artificial Pancreas

Model Predictive Control (MPC) of an Artificial Pancreas with Data-Driven Learning of Multi-Step-Ahead Blood Glucose Predictors

Intermittent closed-loop blood glucose control for people with type 1 diabetes on multiple daily injections

A practical approach based on learning-based model predictive control with minimal prior knowledge of patients for artificial pancreas

Embedded Model Predictive Control for a Wearable Artificial Pancreas

An event-triggered active disturbance rejection approach to dual-hormonal artificial pancreas control

Event-Triggered Model Predictive Control for Artificial Pancreas Using Prior-Knowledge-Informed Hybrid Model

Glucose Regulation for Subjects with Type 1 Diabetes Using Active Disturbance Rejection Control

Adaptive Zone Model Predictive Control of Artificial Pancreas Based on Glucose- and Velocity-Dependent Control Penalties

Glucose Outcomes of a Learning-Type Artificial Pancreas with an Unannounced Meal in Type 1 Diabetes.

CHoKI-based MPC for blood glucose regulation in Artificial Pancreas

Run-to-Run Tuning of Model Predictive Control for Type 1 Diabetes Subjects: In Silico Trial

Simultaneous model predictive control and moving horizon estimation for blood glucose regulation in Type 1 diabetes

Delayed prandial insulin boluses are an important determinant of blood glucose control and relate to fear of hypoglycemia in people with type 1 diabetes on advanced technologies

Zone Model Predictive Control with Glucose- and Velocity-Dependent Control Penalty Adaptation for an Artificial Pancreas.

Performance Analysis of Different Embedded Systems and Open-Source Optimization Packages Towards an Impulsive MPC Artificial Pancreas

Simplified Meal Management in Adults Using an Advanced Hybrid Closed-Loop System

Design of reduced multiple model predictive controller for glucose–insulin regulation in type 1 diabetic patients